Zwitterionic Metal Chelators with Balanced Charge for Low Background
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing metal chelators lack solubility in aqueous environments, result in non-specific interactions, and have poor pharmacokinetics, leading to high background and toxicity in medical and chemical processes, and inadequate yield in agricultural processes.
Innovation Solution
Development of zwitterionic metal chelators with balanced formal charges and extended hydration spheres, minimizing non-specific interactions and enhancing solubility, allowing rapid equilibration and efficient clearance from the body.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If common metal chelators (DOTA, PyC3A, macropa) are used, then metal binding is achieved, but solubility in aqueous environments is poor and non-specific interactions occur
Solution Approach 1:
The patent applies parameter changes by modifying the charge state of the chelator from anionic to zwitterionic. This fundamental parameter change in the molecular structure transforms the interaction profile with aqueous environments and biological tissues, achieving both high solubility and reduced non-specific binding through balanced positive and negative charges.
Solution Approach 2:
The invention creates composite molecular structures combining the metal-chelating core with zwitterionic side chains or substituents. This composite approach integrates the metal-binding functionality with solubility-enhancing and interaction-minimizing zwitterionic moieties, achieving multiple objectives simultaneously.
2Reliability
If common metal chelators are used, then metal complex formation is achieved, but pharmacokinetics are poor resulting in accumulation in off-target tissues
Solution Approach 1:
The patent changes the charge parameter from anionic to zwitterionic, which fundamentally alters the pharmacokinetic profile. The zwitterionic character enables rapid equilibration between intravascular and extravascular spaces and facilitates efficient renal clearance while maintaining metal complex stability through the preserved chelating core structure.
3Adaptability or versatility
If carboxylic acid arms are replaced with targeting vectors, then targeting capability is improved, but chelating properties deteriorate
Solution Approach 1:
The patent applies segmentation by separating the targeting function from the chelating function. The zwitterionic groups provide the targeting and pharmacokinetic benefits, while the core chelating structure remains intact to maintain metal-binding properties. This functional segmentation allows both capabilities to coexist without interference.
Solution Approach 2:
The invention applies local quality by placing zwitterionic groups at specific locations on the chelator molecule. This localized modification enables targeting and solubility enhancement without affecting the metal-binding site, preserving chelating properties while adding desired functionality.
4Reliability
If anionic chelators are used, then metal binding is achieved, but signal-to-background ratio in imaging is reduced
Solution Approach 1:
The patent changes the charge parameter from anionic to zwitterionic, which reduces non-specific binding to tissues and background signal while maintaining metal chelation stability. The balanced charge distribution of zwitterions minimizes electrostatic interactions with non-target tissues, thereby improving the signal-to-background ratio in imaging applications.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Improves signal-to-background ratio and therapeutic window in medical imaging, reduces toxicity, and enhances process yield by minimizing non-specific interactions and facilitating rapid clearance.
Implementation Method 1
whenever they are needed in a medical, agricultural, or chemical process they must be bound to, e.g. by coordination or chelation, to an organic compound
Implementation Method 2
pay little attention to the polyionicity and sphere of hydration that is required to fully isolate the metal
Data Source
AI summary
The present invention relates to zwitterionic metal chelators and their use as imaging, diagnostic, chemical processing, and treatment agents. These zwitterionic metal chelators have desirable properties that maximize solubility in aqueous environments, minimize non-specific interactions, and retain the ability to target thus resulting in an improved performance in a variety of medical, agricultural, and chemical processes. In in vivo and medical applications, zwitterionic metal chelators improve the signal-to-background ratio and therapeutic window as compared to other metal chelators while retaining high stability.